Toggle light / dark theme

Real-time social interactions reveal how we balance cooperation and competition

When people reach for the same object, walk through a narrow doorway, forage for food, or work together on a shared task, they continuously negotiate—often without noticing—how much to cooperate or compete. Unlike classical laboratory games that force players to choose between fixed options in advance, real-life interactions unfold dynamically, with movement timing and subtle cues shaping social behavior from one moment to the next.

A collaborative research team from the Max Planck Institute for Dynamics and Self-Organization (MPI), the University of Göttingen, and the German Primate Center—Leibniz Institute for Primate Research (DPZ) has developed a novel experimental framework that captures this natural complexity. Their study, published in Communications Psychology, reveals how human pairs spontaneously settle into stable cooperative, intermediate or competitive roles—and how these strategies arise from the interplay between social motives, cost-benefit constraints, and sensorimotor skills.

Ultra-low power, fully biodegradable artificial synapse offers record-breaking memory

In Nature Communications, a research team affiliated with UNIST present a fully biodegradable, robust, and energy-efficient artificial synapse that holds great promise for sustainable neuromorphic technologies. Made entirely from eco-friendly materials sourced from nature—such as shells, beans, and plant fibers—this innovation could help address the growing problems of electronic waste and high energy use.

Traditional artificial synapses often struggle with high power consumption and limited lifespan. Led by Professor Hyunhyub Ko from the School of Energy and Chemical Engineering, the team aimed to address these issues by designing a device that mimics the brain’s synapses while being environmentally friendly.

30,000 Brain Scans Reveal a Hidden Danger in Ultra-Processed Foods

Brain imaging of 30,000 people revealed that ultra-processed foods are associated with structural differences in the brain that could fuel overeating.

The study suggests that additives like emulsifiers may influence these effects. While some processed foods are beneficial, ultra-processed products pose a clear risk.

Brain imaging study reveals concerning links to ultra-processed foods.

How to build a genome: Scientists release troubleshooting manual for synthetic life

Leading synthetic biologists have shared hard-won lessons from their decade-long quest to build the world’s first synthetic eukaryotic genome in a Nature Biotechnology paper. Their insights could accelerate development of the next generation of engineered organisms, from climate-resilient crops to custom-built cell factories.

“We’ve assembled a comprehensive overview of the literature on how to build a lifeform where we review what went right—but also what went wrong,” says Dr. Paige Erpf, lead author of the paper and postdoctoral researcher at Macquarie University’s School of Natural Sciences and the Australian Research Council (ARC) Center of Excellence in Synthetic Biology.

The Synthetic Yeast Genome Project (Sc2.0) involved a large, evolving global consortium of 200-plus researchers from more than ten institutions, who jointly set out to redesign and chemically synthesize all 16 chromosomes of baker’s yeast from scratch. Macquarie University contributed to the synthesis of two of these chromosomes, comprising around 12% of the project overall.

Antibacterial and Immunostimulatory Activity of Potential Probiotic Lactic Acid Bacteria Isolated from Ethiopian Fermented Dairy Products

Lactic acid bacteria (LAB) form a group of bacteria to which most probiotics belong and are commonly found in fermented dairy products. Fermented foods and beverages are foods made through desired microbial growth and enzymatic conversions of food components. In this study, 43 LAB were isolated from Ethiopian traditional cottage cheese, cheese, and yogurt and evaluated for their functional and safety properties as candidate probiotics. Twenty-seven isolates, representative of each fermented food type, were selected and identified to the species level. Limosilactobacillus fermentum was found to be the predominant species in all samples studied (70.4%), while 11.1% of isolates were identified as Lactiplantibacillus plantarum. All 27 isolates tested showed resistance to 0.5% bile salt, while 26 strains were resistant to pH 3.

Body image issues in adolescence are linked to depression in adulthood, twin study finds

Teenagers who are unhappy with their bodies are more likely to develop symptoms of eating disorders and depression in early adulthood, according to a new study led by University College London (UCL) researchers.

The research, believed to be the first of its kind, followed more than 2,000 twins born in England and Wales. It found that higher body dissatisfaction at age 16 predicted greater symptoms of eating disorders and depression well into the twenties, even after taking into account family background and genetics.

Researchers say the findings strengthen evidence that a negative body image is not just a reflection of poor mental health, but that it can also contribute to it.

Medications change our gut microbiome in predictable ways

The bacteria in our poop are a reasonable representation of what’s living in our digestive system. To understand how different drugs can impact the gut microbiome, the team cultured microbial communities from nine donor fecal samples and systematically tested them with 707 different clinically relevant drugs.

The researchers examined changes in the growth of different bacterial species, the community composition, and the metabolome – the mix of small molecules called metabolites that microbes produce and consume. They found that 141 drugs altered the microbiome of the samples and even short-term treatments created enduring changes, entirely wiping out some microbial species. The primary force behind how the community responds to drug inhibition was competition over nutrients.

“The winners and losers among our gut bacteria can often be predicted by understanding how sensitive they are to the medications and how they compete for food,” said the first author on the paper. “In other words, drugs don’t just kill bacteria; they also reshuffle the ‘buffet’ in our gut, and that reshuffling shapes which bacteria win.”

Despite the complexity of the bacterial communities, the researchers were able to create data-driven computer models that accurately predicted how they would respond to a particular drug. They factored in the sensitivity of different bacterial species to that drug and the competitive landscape – essentially, who was competing with whom for which nutrients.

Their work provides a framework for predicting how a person’s microbial community might change with a given drug, and could help scientists find ways to prevent these changes or more easily restore a healthy gut microbiome in the future.


Our gut microbiome is made up of trillions of bacteria and other microbes living in our intestines. These help our bodies break down food, assist our immune system, send chemical signals to our brain, and potentially serve many other functions that researchers are still working to understand. When the microbiome is out of balance – with not enough helpful bacteria or the wrong combination of microbes – it can affect our whole body.

Ozempic can reduce metabolic risks in schizophrenia patients, multicenter study finds

Semaglutide medications like Ozempic and Wegovy can help lower the risk of heart and metabolic diseases in people with schizophrenia spectrum disorders, according to a study published in JAMA Psychiatry.

Glucagon-like peptide–1 receptor agonist (GLP-1RAs) drugs, such as semaglutide, mimic the natural gut hormone GLP-1 that regulates hunger and food intake. By activating GLP-1 receptors in the brain, the drug reduces hunger and slows gastric emptying, helping one feel full longer. It also enhances glucose-dependent insulin secretion, thereby improving blood sugar control.

Researchers in Denmark recruited 73 adults taking antipsychotic medications who were showing early signs of diabetes and had an average BMI of 36, which falls in the category of obesity. The participants, aged 18 to 65 years, were randomly assigned to receive either weekly semaglutide injections or a placebo for 6.5 months.

/* */